179 related articles for article (PubMed ID: 28449314)
1. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Kinjyo I; Matlawska-Wasowska K; Chen X; Monks NR; Burke P; Winter SS; Wilson BS
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449314
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.
Müller F; Stookey S; Cunningham T; Pastan I
Oncotarget; 2017 May; 8(19):30644-30655. PubMed ID: 28423727
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Short NJ; Kantarjian H; Jabbour E; Cortes JE; Thomas DA; Rytting ME; Daver N; Alvarado Y; Konopleva M; Kebriaei P; Wierda WG; DiNardo CD; Bivins C; McCue D; Richie MA; Ravandi F
Br J Haematol; 2018 Aug; 182(3):442-444. PubMed ID: 28616864
[No Abstract] [Full Text] [Related]
4. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
5. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN; Bhojwani D; August K; Baruchel A; Bertrand Y; Boklan J; Dalla-Pozza L; Dennis R; Hijiya N; Locatelli F; Martin PL; Mechinaud F; Moppett J; Rheingold SR; Schmitt C; Trippett TM; Liang M; Balic K; Li X; Vainshtein I; Yao NS; Pastan I; Wayne AS
Pediatr Blood Cancer; 2020 May; 67(5):e28112. PubMed ID: 31944549
[TBL] [Abstract][Full Text] [Related]
6. Moxetumomab Pasudotox: First Global Approval.
Dhillon S
Drugs; 2018 Nov; 78(16):1763-1767. PubMed ID: 30357593
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.
Liu X; Müller F; Wayne AS; Pastan I
Mol Cancer Ther; 2016 May; 15(5):1053-62. PubMed ID: 26939705
[TBL] [Abstract][Full Text] [Related]
8. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
9. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
10. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
11. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Haso W; Lee DW; Shah NN; Stetler-Stevenson M; Yuan CM; Pastan IH; Dimitrov DS; Morgan RA; FitzGerald DJ; Barrett DM; Wayne AS; Mackall CL; Orentas RJ
Blood; 2013 Feb; 121(7):1165-74. PubMed ID: 23243285
[TBL] [Abstract][Full Text] [Related]
12. Domain II of
Müller F; Cunningham T; Beers R; Bera TK; Wayne AS; Pastan I
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29883379
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.
Wang B; Liang M; Yao Z; Vainshtein I; Lee R; Schneider A; Zusmanovich M; Jin F; O'Connor K; Donato-Weinstein B; Iciek L; Lavallee T; Roskos L
J Pharm Sci; 2013 Jan; 102(1):250-61. PubMed ID: 23090886
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.
Satake N; Duong C; Chen C; Barisone GA; Diaz E; Tuscano J; Rocke DM; Nolta J; Nitin N
Br J Haematol; 2014 Nov; 167(4):487-99. PubMed ID: 25196579
[TBL] [Abstract][Full Text] [Related]
16. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
17. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
Yoshida S; Tuscano E; Duong C; Chung J; Li Y; Beckett L; Tuscano JM; Satake N
Leuk Lymphoma; 2017 May; 58(5):1254-1257. PubMed ID: 27701909
[No Abstract] [Full Text] [Related]
18. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
Bera TK; Onda M; Kreitman RJ; Pastan I
Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
[TBL] [Abstract][Full Text] [Related]
19. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
Mussai F; Campana D; Bhojwani D; Stetler-Stevenson M; Steinberg SM; Wayne AS; Pastan I
Br J Haematol; 2010 Aug; 150(3):352-8. PubMed ID: 20528877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
